EGFR and neoplasm: Currently, there are two identified molecular subtypes of NSCLC that have targeted therapies approved for their treatment: mutations in the epidermal growth factor receptor (EGFR) gene and rearrangements in the anaplastic lymphoma kinase (ALK) gene; tumours harbouring these genetic alterations respond well to specific tyrosine kinase inhibitors [2, 3].